Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5441_Библиотеки_им_академика_М_И_Перельмана.pdf
98
potential to reduce the concentration of the API and generate hazardous impurities.
Additionally, ionisable drugs may undergo reactions with ionised, soluble additives,
resulting in the formation of insoluble products. Studies have shown that the exis-
tence of residual reactive impurities in additives contributes to the degradation of
the drug product. Specically, the oxidative degradation of polyethylene glycol and
polysorbate additives can lead to the initial formation of aldehyde impurities. These
aldehyde impurities have the potential to undergo further oxidation, ultimately
resulting in the generation of both formic and acetic acids (Sharma 2019). These
chemical transformations underscore the importance of carefully considering the
choice of solvent and additives in pharmaceutical formulations to ensure stability
and prevent the formation of undesirable by-products.
4.4.3 Therapeutic or Physiological Incompatibilities
Therapeutic incompatibilities arise when a patient’s reaction to one or more medica-
tions differs from the doctor’s expected course of action or degree of effect. These
interactions occur within the biological system in the presence of an aqueous envi-
ronment. This type of interaction signicantly inuences the absorption of API in
the biosystem, thereby affecting their pharmacological activity. The pH of gastric
uid plays a crucial role in drug absorption from the gastrointestinal (GI) environ-
ment, inuencing the solubility and ionisation of pharmaceutical drugs. Alterations
in gastric transit time, inuenced by coadministered drugs or additives, directly
impact the bioavailability of consumed drugs. Furthermore, GI motility, affected by
various formulations such as lipid-based dosage forms, can contribute to variability
in drug absorption (Soni etal. 2016). Additionally, alterations in drug metabolism
in the liver, mediated by enzymes like cytochrome P-450, can affect drug concentra-
tion, leading to potential toxicities or loss of pharmacological activity. The involve-
ment of P-glycoprotein efux transporter in multidrug-resistant cells, and the
incorporation of specic additives in pharmaceutical formulations to inhibit P-gp,
demonstrates the complicated relationship between physiological interactions and
drug availability, particularly in cancer treatment (Choudhury et al. 2017).
Addressing therapeutic incompatibility is crucial in pharmaceutical development to
ensure that the nal product delivers the intended therapeutic benets while main-
taining stability and safety. Researchers and formulators strive to design formula-
tions that minimise the risk of incompatibility, enhancing the overall quality and
effectiveness of pharmaceutical products.
4.4.4 Analytical Techniques toCharacterise
Drug-Additive Incompatibility
In order to reduce or mitigate the unfavourable responses brought on by the
incompatibility, scientists use a variety of analytical techniques for its detection.
Thermal methods like hot stage microscopy, isothermal microcalorimetry,
M. Patel etal.
99
thermogravimetric analysis, differential scanning calorimetry and X-ray diffraction
assess thermal events, crystallinity and polymorphism, which are vital in perform-
ing compatibility screening studies (Rojek and Wesolowski 2023). Technique like
high-performance liquid chromatography enables the separation and quantication
of individual components, aiding in the identication of degradation products and
monitoring changes in composition (Al-Rifai et al. 2022). Furthermore, Fourier
transform infrared spectroscopy elucidates molecular structures by measuring infra-
red radiation absorption, offering insights into chemical changes and functional
groups (Rojek et al. 2023). Nuclear magnetic resonance spectroscopy provides
detailed information on molecular conformation and interactions between drug and
additives (Velip etal. 2023). Mass spectrometry and UV-visible spectroscopy offer
quantitative analysis and identication of chemical entities, while electrophoretic
techniques can reveal charge-related interactions (Pan et al. 2023; Mishra et al.
2023). In recent times, spectroscopic techniques including near-infrared and solid-
state nuclear magnetic resonance spectroscopy have been employed to examine
moisture present in the drug or interactions between drug and additive, which could
lead to the instability of active principles. These methods vary based on their theory,
sample machine and temperature stress, required testing duration, sample number,
sensitivity to small changes and demand for either internal or external requirements.
Real-time stability studies and particle size analysis contribute further to a compre-
hensive understanding of drug-additive compatibility, ensuring the quality and
safety of pharmaceutical formulations. Finally, studies reveal that the combination
of thermal and nonthermal methods proves to be an effective approach for identify-
ing incompatibilities between drugs and additives (Xie etal. 2023).
4.5 Recent Advances inAdditive Science
Recent advances in pharmaceutical formulation additive science have revolution-
ised drug delivery, efcacy and patient experience. One notable breakthrough
involves the development of multifunctional additives including functional and co-
processed additives. These additives serve multiple purposes, such as improving
drug solubility, stability and bioavailability. Co-crystallisation techniques, where
two or more compounds are combined to form a new crystalline structure, have
been employed to enhance the physical properties of drugs. An example is the co-
crystallisation of the antiretroviral drug ritonavir with saccharin, which improves its
solubility and bioavailability (Varshosaz etal. 2018). Polymeric additives, such as
copovidone and hypromellose acetate succinate, are also gaining prominence
(Vadlamudi and Dhanaraj 2017; Mašková etal. 2020). These polymers not only
serve as binders and llers but also contribute to the controlled release of drugs.
They enhance the stability of formulations and assist in achieving the desired drug
release proles. Co-processing techniques, where multiple additives are combined
to create a single multifunctional excipient, represent another notable advancement.
For instance, the co-processing of lactose with microcrystalline cellulose results in
a multifunctional excipient that improves tablet hardness, disintegration and drug
4 Pharmaceutical Product Development: Formulation Additives
100
release. Moreover, the integration of smart polymers and hydrogels into pharmaceu-
tical formulations has opened avenues for controlled drug release by responding to
external stimuli. These advancements not only contribute to the development of
more effective and patient-specic medications but also prompt a surge in patent
lings to protect these innovative technologies globally. Some of the internationally
patented additives are given in Table4.1. Despite the regulatory authorities’ recom-
mendations, the rms that manufacture drug products restrict the use of innovative
additives since they are required to provide clinical safety data to the agencies
before the additive may be used in a product (Pérez etal. 2020).
4.5.1 Functional andCo-processed Additives
To address the needs of formulation experts regarding production costs, improved
additive functionality and tablet quality, formulation scientists decided to focus
their efforts on developing multifunctional additives with improved performance.
Due to their extensive utilisation across various purposes, additives are now consid-
ered functional ingredients rather than remaining inactive components. Single-
component additives might sometimes lack the performance needed to achieve the
desired functionality for formulating or manufacturing specic drugs. Hence, co-
processing has become pivotal in designing stable additives with multiple function-
alities. These additives stand as innovative blends in pharmaceutical formulations,
combining the strengths of both natural and synthetic components. Natural co-
processed additives often merge plant-based materials or polysaccharides with syn-
thetic polymers to create stable, multifunctional additives. The blending of natural
or synthetic polymers has extensively been studied to create innovative, stable co-
processed additives. Plant-based component co-processing has emerged as a signi-
cant advantage for numerous pharmaceutical industries globally in recent times
(Bhatia etal. 2022). These combinations harness the inherent advantages of natural
sources, such as biocompatibility and sustainability, while leveraging the precision
and consistency offered by synthetic compounds. Synthetic co-processed additives,
on the other hand, result from particular engineering to fuse specic functionalities,
enhancing ow properties, compressibility or disintegration rates. Their tailored
composition allows for modication of drug formulations to meet targeted release
proles, stability requirements and manufacturing efciency, exemplifying the syn-
ergy achieved through the combination of natural and synthetic elements in pharma-
ceutical development.
The characteristics of additives can be readily modied extensively through co-
processing or particle engineering methods. During co-processing method, addi-
tives interact at a sub-particle level to enhance the combined benecial properties of
both additives. Simultaneously, the aim is to hide any undesirable characteristics
inherent in each additive. Typically, this is accomplished through co-drying and co-
precipitation methods. Both additives are dispersed within a solvent and then dried,
yielding a physical mixture adjusted to a targeted size range. Particle size, shape,
surface area, porosity, density and other basic solid-state characteristics affect
M. Patel etal.
101
Table 4.1 List of international patented additives
Patent number
Title Additives Uses
References
US10555912B2 Use of
polymeric
excipients for
lyophilisation
or freezing of
particles
Polyvinyl alcohols,
optionally in
conjunction with
sugars
Cryoprotectant Foss and
Shinde
(2018)
US20180055939A1 Excipients for
use in
adeno-
associated virus
pharmaceutical
formulations
and
pharmaceutical
formulations
made therewith
Sorbitol and Tween
20 and Tween 80
Diluent Sista and
Espinoza
(2017)
EP3441074A1 Novel vehicles
for the
transfection of
miRNAs
Span and Tween Nonionic
surfactants
Sanchez
etal.
(2017)
US20120289536A1 Pharmaceutical
compositions
comprising
colloidal silicon
dioxide
Colloidal silicon
dioxide and
cross-linked
polyvinylpyrrolidone
Disintegrants Haeberlin
and
Kramer
(2012)
US20130177649A1 Co-processed
tablet excipient
composition, its
preparation and
use
Co-processed
additive comprising
40%to70% lactose,
20%to50% MCC,
1%to10%
cross-linked sodium
starch glycolate and
0.2%to1% lubricant
Filler, binder,
disintegrant and
lubricant,
respectively
Van Gessel
(2010)
US8513329B2 Chemical
additives to
make polymeric
materials
biodegradable
Furanone and carrier
resin
For enhancing
biodegradation
of polymeric
material
Lake and
Adams
(2008)
(continued)
4 Pharmaceutical Product Development: Formulation Additives
102
Table 4.1 (continued)
Patent number
Title Additives Uses
References
US8932629B2 Co-processed
microcrystalline
cellulose and
sugar alcohol as
an excipient for
tablet
formulations
Co-processed
microcrystalline
cellulose and
mannitol
Improving
compressibility,
lubricant
affectability and
ejection prole
Li etal.
(2007)
US20040228932A1 Pharmaceutical
excipient
Multifunctional
bre-rich fraction
(FRF)
Binder,
disintegrant,
ller, dispersing
agent, coating
agent,
lm-forming
agent, thickener,
etc.
Pilgaonkar
etal.
(2003)
US5989589A Cross-linked
cellulose as
some tablet
excipients
Cross-linked
cellulose
Binder and
disintegrant
Cartilier
and Chebli
(1997)
US5585115A Pharmaceutical
excipient
having
improved
compressibility
Combination of
MCC particles and
silicon dioxide
particles
Improves
Compressibility,
regardless of
whether used in
direct
compression,
dry granulation
or wet
granulation
formulations
Sherwood
etal.
(1995)
US5128143A Sustained
release
excipient and
tablet
formulation
Xanthan gum and
galactomannan gum
Cross-linking
agents at gastric
pH
Baichwal
and
Staniforth
(1990)
US5004601A Low-melting
mouldable
pharmaceutical
excipient and
dosage forms
prepared
therewith
Low molecular
weight PEG,
medium to high
molecular weight
PEG long-chain
saturated carboxylic
acid polyethylene
oxide and colloidal
silica
Mouldable
pharmaceutical
excipients
having low
melting point
Snipes
(1988)
US4762857A Trehalose as
stabiliser and
tableting
excipients
Trehalose Stabiliser Ernest
Bollin and
Fletcher
(1987)
M. Patel etal.
103
additive capabilities such as compatibility, owability, dilution potential, disintegra-
tion potential and lubricating potential. Therefore, designing a particle that will
yield the required capabilities must come rst when developing a novel additive.
4.5.2 Novel Materials andMulti-Materials
The eld of pharmaceutical formulations has witnessed a transformative shift with
the incorporation of novel materials and multi-material additives, revolutionising
drug delivery and therapeutic efcacy. Nanotechnology has emerged as a corner-
stone, with lipid nanoparticles (LNPs) and polymeric nanoparticles at the forefront.
LNPs exhibit exceptional capabilities in enhancing drug solubility and stability, sig-
nicantly improving bioavailability. Meanwhile, polymeric nanoparticles enable
controlled drug release and targeted delivery, paving the way for personalised medi-
cine. The discovery of 3D printing and multi-material additive manufacturing has
further propelled innovation by allowing the creation of intricate dosage forms with
distinct material properties (Lee etal. 2017). Co-crystals, formed by combining API
with co-crystal formers, contribute to improved drug solubility and stability.
Hydrogels, particularly smart hydrogels responsive to environmental stimuli, pro-
vide dynamic drug release proles. The utilisation of polymeric additives, such as
biodegradable polymers, has become integral to encapsulating drugs for sustained
release. Graphene, carbon nanotubes and metal-organic frameworks offer unique
properties for drug delivery, while traditional components like cyclodextrins con-
tinue to play a crucial role in enhancing drug solubility. This amalgamation of novel
materials and multi-material additives not only addresses long-standing challenges
in drug formulation but also opens avenues for the development of advanced,
patient-centric pharmaceutical products with improved therapeutic outcomes.
4.6 Related Regulatory Perspectives
The regulatory aspect of pharmaceutical additives is an essential aspect for ensuring
the safety and efcacy of medicinal products. Any component of a drug product
other than the active ingredient is considered an inactive ingredient, i.e. additive, as
dened by 21 CFR 210.3(b)(8). Regulatory bodies, including the U.S.Food and
Drug Administration (FDA) and the European Medicines Agency (EMA), closely
monitor the use of pharmaceutical additives through stringent guidelines. The regu-
latory guidelines governing pharmaceutical additives include several key perspec-
tives, including those outlined by the International Pharmaceutical Excipients
Council (IPEC), generally recognised as safe (GRAS) status and the Inactive
Ingredient Guide (IIG).
4 Pharmaceutical Product Development: Formulation Additives
104
4.6.1 GRAS
In the United States, the GRAS status holds particular signicance in the regulatory
perspectives of pharmaceutical additives. The GRAS designation, overseen by the
FDA, signies that a substance is considered safe for consumption based on scien-
tic evidence. While GRAS primarily applies to food ingredients, it is relevant to
pharmaceutical additives that may nd dual utility in both drug formulations and
food products (Manchanda et al. 2018). Sections 201(s) and 409 of the Federal
Food, Drug, and Cosmetic Act, which governs how the FDA reviews and approves
certain compounds, serve as the foundation for GRAS.Generally speaking, a mate-
rial can be added to the GRAS components list if it has completed the necessary
safety evaluation conducted by a group of professionals and found not to be harmful
when used as intended. The GRAS list’s primary goals are to ensure consumers that
the goods they are eating are healthy and safe while also accelerating the approval
and launch of new items onto the market. A manufacturer may add an ingredient to
human food items without rst obtaining FDA permission, even though the FDA is
responsible for premarket approval of food additives. This is as long as the compo-
nent is deemed GRAS for the intended application. Imagine if every time a new
product was introduced to the market, regulatory bodies like the US FDA had to
evaluate every component from scratch. In addition to placing a burden on regula-
tory bodies’ human resources, this would also force new product makers to resubmit
data on these components. Alternatively, by simply adding these components to
their goods without needing to le for new approvals, producers and scientists may
easily generate new products and full new needs, thanks to a pre-approved list of
additives. Presently, slightly more than 370 compounds have been granted GRAS
status; many of them are also authorised additives that have monographs in the
European Pharmacopoeia, Japanese Pharmacopoeia or United States
Pharmacopeia—National Formulary. Additives that are listed as GRAS often con-
sist of natural, synthetic or semisynthetic components. When an additive is desig-
nated as GRAS, it basically indicates that an expert scientic committee has decided
their intended use, and the FDA will not examine it prior to market release. By
mandating producers to give information required by authorities and consumers on
the safety of substances introduced into consumer products, the GRAS framework
offers an extra safeguard for the welfare of the public.
4.6.2 IIG
IIG serves as a comprehensive reference for pharmaceutical manufacturers, provid-
ing detailed information on permissible inactive ingredients in drug formulations. It
outlines acceptable additives and their respective specications, offering guidance
to industry professionals to ensure compliance with regulatory standards. The phar-
maceutical industry can utilise this information to help in the development of new
drugs. When an inactive component surfaces in an authorised drug product for a
specic route of administration, it is no longer deemed novel for the goal of
M. Patel etal.
105
developing novel drugs, and the next time it appears in a new drug product, it could
need a less thorough assessment. For instance, a sponsor may believe that an inac-
tive component is safe to employ in a comparable way for a comparable kind of
product if it has been approved in a certain dosage form at a specic
concentration.
The IIG, published by the US Food and Drug Administration (FDA), serves as a
reference for acceptable inactive ingredients in pharmaceutical products. The
Chemical Abstracts Service registry (CAS) is a section of the American Chemical
Society that offers extensive electronic services for chemical information. It pro-
vides unique numerical identiers for chemical substances, helping to accurately
identify and track these substances. Additionally, the Unique Ingredient Identier
(UNII) system, managed by the FDA, assigns a unique alphanumeric code to each
substance, enhancing precision in ingredient identication. In practical terms, when
a pharmaceutical manufacturer refers to the IIG for guidance on suitable additives,
the listed ingredients are often identied by their CAS numbers. The UNII system,
with its unique identiers, adds an additional layer of specicity in tracking and
communication. Collectively, these regulatory tools work together to ensure preci-
sion, consistency and compliance in the use of pharmaceutical additives, facilitating
regulatory approvals and the development of safe and effective medicines. Together,
the IIG, CAS and UNII contribute to a robust regulatory framework, facilitating the
development and approval of pharmaceutical products with a focus on safety, ef-
cacy and quality.
4.6.3 IPEC
IPEC is a global organisation committed to establishing and promoting standards
for additives used in pharmaceutical products (DeMerlis etal. 2016). The council
provides guidelines and best practices for the development, manufacturing and
quality control of pharmaceutical additives, contributing to the overall safety and
efcacy of drug formulations. By offering a harmonised approach to excipient stan-
dards, IPEC facilitates international collaboration and ensures a consistent regula-
tory framework across different regions. The federation has recommended guidelines
for the safety assessment of new additives and good manufacturing practices for
bulk pharmaceutical additives, ensuring comprehensive information for the safe use
of these substances. Pharmacopoeial harmonisation, managed by the Pharmacopoeial
Discussion Group (PDG), has played a signicant role in streamlining regulatory
processes for additives, contributing to their quality, safety and efcacy. As of 2017,
signicant progress has been made in harmonising chapters and monographs across
different pharmacopoeias (IPEC Federation 2023). Presently, IPEC Europe holds
the presidency, while IPEC-Americas and IPEC Japan serve as vice president and
treasurer, respectively. Manufacturers adhering to IPEC guidelines demonstrate a
commitment to producing high-quality pharmaceuticals, contributing to the con-
dence of regulatory agencies and fostering global acceptance of their products.
4 Pharmaceutical Product Development: Formulation Additives
106
4.7 Conclusion
This chapter offers a comprehensive survey of the multifaceted world of formula-
tion additives in the pharmaceutical industry. The elucidation begins with a thor-
ough introduction, setting the stage for a detailed examination of the importance of
additives in shaping the development of pharmaceutical dosage forms. By elucidat-
ing the importance of additives in achieving desired characteristics and functional-
ities, the chapter highlights their essential role as formulation aids. There are various
types of formulation additives that are tailored to meet the diverse requirements of
oral solids, liquids, transdermal and parenteral dosage forms. However, prior to
incorporating any particular additive into formulation development, it is crucial to
conduct thorough drug-additive interaction studies. The interaction studies provide
important insights into the complexities inherent in formulation development,
emphasising the need for thorough understanding and mitigation of physical, chem-
ical and therapeutic incompatibilities. Despite the growing demand for new addi-
tives due to advancements in drug product development, it remains imperative to
carefully consider the regulatory aspects surrounding their usage. Notably, there is
no singular universal regulatory guideline governing pharmaceutical additives,
necessitating compliance with a combination of international, regional and national
standards and regulations. It can be concluded that there are huge possibilities and
future directions in the development of additives, suggesting potential avenues for
further advancement in pharmaceutical formulation technology. Since formulations
cannot be created without additives, this chapter stands as an essential resource for
individuals involved in the development of pharmaceutical products.
References
Abrantes CG, Duarte D, Reis CP (2016) An overview of pharmaceutical excipients: safe or not
safe? J Pharm Sci 105(7):2019–2026. https://doi.org/10.1016/j.xphs.2016.03.019
Adamkiewicz L, Szeleszczuk Ł (2023) Review of applications of cyclodextrins as taste- masking
excipients for pharmaceutical purposes. Molecules 28(19):6964. https://doi.org/10.3390/
molecules28196964
Al-Rifai N, Alshishani A, Saad B, Rasras A, Zahra J, Madieh S, Darras F (2022) Synthesis, isola-
tion, identication and characterization of a drug-excipient interaction degradation impurity
in pramipexole by HPLC, LC/MS and NMR. Separations 10(1):7. https://doi.org/10.3390/
separations10010007
Al-Rubaye IM (2022) A review of the literature on antimicrobial preservatives: denition, proper-
ties, classication, safety, side effects and antimicrobial effectiveness testing. Atena J Public
Health 4:7
Bácskay I, Hosszú Z, Budai I, Ujhelyi Z, Fehér P, Kósa D, Haimhoffer Á, Pető Á (2023) Formulation
and evaluation of transdermal patches containing BGP-15. Pharmaceutics 16(1):36. https://doi.
org/10.3390/pharmaceutics16010036
Baichwal AS, Staniforth JN (1990) Sustained release excipient and tablet formulation.
US5128143A
Balasubramaniam J, Bindu K, Rao VU, Ray D, Haldar R, Brzeczko AW (2008) Effect of superdis-
integrants on dissolution of cationic drugs. Dissolut Technol 15(2):18. https://doi.org/10.14227/
DT150208P18
M. Patel etal.
107
Ballentine C (1981) Sulfanilamide disaster. FDA Consumer Mag 5. https://www.fda.gov/les/
about%20fda/published/The- Sulfanilamide- Disaster.pdf
Banerjee S, Chattopadhyay P, Ghosh A, Datta P, Veer V (2014) Aspect of adhesives in trans-
dermal drug delivery systems. Int J Adhes Adhes 50:70–84. https://doi.org/10.1016/j.
ijadhadh.2014.01.001
Bejaoui M, Kalfat R, Galai H (2021) The effect of adding PVP to the binary solid dispersion
(indomethacin: kaolin) on the formation of physically stable amorphous drug. J Pharm Innov
17:736. https://doi.org/10.1007/s12247- 021- 09553- 6
Bhatia V, Dhingra A, Chopra B, Guarve K (2022) Co-processed excipients: recent advances
and future perspective. J Drug Deliv Sci Technol 71:103316. https://doi.org/10.1016/j.
jddst.2022.103316
Bjelošević M, Pobirk AZ, Planinšek O, Grabnar PA (2020) Excipients in freeze-dried biopharma-
ceuticals: contributions toward formulation stability and lyophilisation cycle optimisation. Int
J Pharm 576:119029. https://doi.org/10.1016/j.ijpharm.2020.119029
Blundell R, Butterworth P, Charlier A, Daurio D, Degenhardt M, Harris D, Hancock B, Johnston
M, Kasina R, Kaye J, Kelly R (2022) The role of titanium dioxide (E171) and the requirements
for replacement materials in oral solid dosage forms: An IQ Consortium Working Group
Review. J Pharm Sci 111:2943. https://doi.org/10.1016/j.xphs.2022.08.011
Bodratti AM, Alexandridis P (2018) Amphiphilic block copolymers in drug delivery: advances in
formulation structure and performance. Expert Opin Drug Deliv 15(11):1085–1104. https://
doi.org/10.1080/17425247.2018.1529756
Cartilier L, Chebli C (1997) Cross-linked cellulose as a tablet excipient. US5989589A
Choudhury H, Gorain B, Pandey M, Kumbhar SA, Tekade RK, Iyer AK, Kesharwani P (2017)
Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy. Int J
Pharm 529(1–2):506–522. https://doi.org/10.1016/j.ijpharm.2017.07.018
Dave VS, Saoji SD, Raut NA, Haware RV (2015) Excipient variability and its impact on dosage
form functionality. J Pharm Sci 104(3):906–915. https://doi.org/10.1002/jps.24299
DeMerlis CC, Smith A, Schoneker DR (2016) Regulatory information for excipients. In:
Pharmaceutical excipients: properties, functionality, and applications in research and industry,
pp241–267. https://doi.org/10.1002/9781118992432.ch6
Desai D, Kothari S, Huang M (2008) Solid-state interaction of stearic acid with povidone
and its effect on dissolution stability of capsules. Int J Pharm 354(1–2):77–81. https://doi.
org/10.1016/j.ijpharm.2007.11.042
Ernest Bollin J, Fletcher MG (1987) Trehalose as stabilizer and tableting excipient. US4762857A
Foss W, Shinde R (2018) Use of polymeric excipients for lyophilization or freezing of particles.
US10555912B2
Gaber DA, Alnwiser MA, Alotaibi NL, Almutairi RA, Alsaeed SS, Abdoun SA, Alsubaiyel AM
(2022) Design and optimization of ganciclovir solid dispersion for improving its bioavailabil-
ity. Drug Deliv 29(1):1836–1847. https://doi.org/10.1080/10717544.2022.2083723
Gabrič A, Hodnik Ž, Pajk S (2022) Oxidation of drugs during drug product development: problems
and solutions. Pharmaceutics 14(2):325. https://doi.org/10.3390/pharmaceutics14020325
Gonçalves RA, Holmberg K, Lindman B (2023) Cationic surfactants: a review. J Mol Liq
2023:121335. https://doi.org/10.1016/j.molliq.2023.121335
Gorain B, Choudhury H, Pandey M, Madheswaran T, Kesharwani P, Tekade RK (2018) Drug–
excipient interaction and incompatibilities. In: Dosage form design parameters. Academic,
pp363–402. https://doi.org/10.1016/B978- 0- 12- 814421- 3.00011- 7
Haeberlin B, Kramer A (2012) Pharmaceutical compositions comprising colloidal silicon dioxide.
US20120289536A1
Indurkhya A, Patel M, Khan MA (2023) Development and characterization of trandolapril imme-
diate release tablets using different superdisintegrating agents. Curr Res Pharm Sci 13:70–77.
https://doi.org/10.24092/CRPS.2023.130106
IPEC (2023) Federation [WWW document]. https://ipec- federation.org/
4 Pharmaceutical Product Development: Formulation Additives